May 09, 2002 (TheStreet.com via COMTEX) -- NaPro BioTherapeutics was soaring
after it and partner Abbott Laboratories received FDA approval to market an
injectable form of the anti-cancer drug paclitaxel.
Paclitaxel is the generic equivalent of Bristol-Myers' Taxol, an anti-tumor
product for treatment of metastatic carcinoma of the ovary or breast cancer
after chemotherapy has failed. The companies said their injectable version will
be available immediately.
NaPro, which makes the raw material used in the treatment in its pact with
Abbott, saw its shares shoot up $10, or about 80%, after announcing the
clearance after the bell Wednesday.
By TSC Staff
(C) 1996 - 2002 TheStreet.com, Inc. All rights reserved.
chart.bigcharts.com/bc3/intchart/frames/...nd=4926&mocktick=1" style="max-width:560px" >
after it and partner Abbott Laboratories received FDA approval to market an
injectable form of the anti-cancer drug paclitaxel.
Paclitaxel is the generic equivalent of Bristol-Myers' Taxol, an anti-tumor
product for treatment of metastatic carcinoma of the ovary or breast cancer
after chemotherapy has failed. The companies said their injectable version will
be available immediately.
NaPro, which makes the raw material used in the treatment in its pact with
Abbott, saw its shares shoot up $10, or about 80%, after announcing the
clearance after the bell Wednesday.
By TSC Staff
(C) 1996 - 2002 TheStreet.com, Inc. All rights reserved.
